Crigna Adriana Torres, Samec Marek, Koklesova Lenka, Liskova Alena, Giordano Frank A, Kubatka Peter, Golubnitschaja Olga
Department of Radiation Oncology, University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany.
Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 03601 Martin, Slovakia.
EPMA J. 2020 Oct 29;11(4):603-627. doi: 10.1007/s13167-020-00226-x. eCollection 2020 Dec.
Interest in the use of cell-free nucleic acids (CFNAs) as clinical non-invasive biomarker panels for prediction and prevention of multiple diseases has greatly increased over the last decade. Indeed, circulating CFNAs are attributable to many physiological and pathological processes such as imbalanced stress conditions, physical activities, extensive apoptosis of different origin, systemic hypoxic-ischemic events and tumour progression, amongst others. This article highlights the involvement of circulating CFNAs in local and systemic processes dealing with the question, whether specific patterns of CFNAs in blood, their detection, quantity and quality (such as their methylation status) might be instrumental to predict a disease development/progression and could be further utilised for accompanying diagnostics, targeted prevention, creation of individualised therapy algorithms, therapy monitoring and prognosis. Presented considerations conform with principles of 3P medicine and serve for improving individual outcomes and cost efficacy of medical services provided to the population.
在过去十年中,人们对使用无细胞核酸(CFNAs)作为临床非侵入性生物标志物组来预测和预防多种疾病的兴趣大幅增加。事实上,循环中的CFNAs可归因于许多生理和病理过程,如应激条件失衡、体育活动、不同来源的广泛细胞凋亡、全身性缺氧缺血事件和肿瘤进展等。本文强调了循环CFNAs在局部和全身过程中的作用,探讨了血液中CFNAs的特定模式、其检测、数量和质量(如甲基化状态)是否有助于预测疾病的发展/进展,并可进一步用于伴随诊断、靶向预防、制定个体化治疗方案、治疗监测和预后评估。本文提出的观点符合3P医学原则,有助于改善个体治疗效果以及提高为民众提供的医疗服务的成本效益。